Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 4
1980 4
1981 2
1982 1
1984 1
1986 1
1987 2
1988 2
1989 2
1990 3
1991 1
1992 4
1993 2
1994 5
1995 2
1996 7
1997 8
1998 7
1999 5
2000 7
2001 12
2002 13
2003 12
2004 16
2005 17
2006 20
2007 16
2008 19
2009 21
2010 18
2011 18
2012 25
2013 22
2014 29
2015 20
2016 23
2017 26
2018 28
2019 16
2020 12
2021 20
2022 21
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

470 results

Results by year

Filters applied: . Clear all
Page 1
Heterogeneity in precision oncology.
Tomasik B, Garbicz F, Braun M, Bieńkowski M, Jassem J. Tomasik B, et al. Among authors: jassem j. Camb Prism Precis Med. 2023 Oct 5;2:e2. doi: 10.1017/pcm.2023.23. eCollection 2024. Camb Prism Precis Med. 2023. PMID: 38549846 Free PMC article. Review.
Stroke heralding granulomatosis with polyangiitis.
Janowiak P, Gorzewska A, Szade J, Bednarska M, Jassem J, Jassem E. Janowiak P, et al. Among authors: jassem j. Pol Arch Intern Med. 2024 Apr 26;134(4):16686. doi: 10.20452/pamw.16686. Epub 2024 Feb 23. Pol Arch Intern Med. 2024. PMID: 38411043 Free article. No abstract available.
Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study.
McLeod M, Torode J, Leung K, Bhoo-Pathy N, Booth C, Chakowa J, Gralow J, Ilbawi A, Jassem J, Parkes J, Mallafré-Larrosa M, Mutebi M, Pramesh CS, Sengar M, Tsunoda A, Unger-Saldaña K, Vanderpuye V, Yusuf A, Sullivan R, Aggarwal A. McLeod M, et al. Among authors: jassem j. Lancet Oncol. 2024 Feb;25(2):e63-e72. doi: 10.1016/S1470-2045(23)00568-5. Lancet Oncol. 2024. PMID: 38301704 Review.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel JL, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Bajetta E, Balko JM, Bellet-Ezquerra M, Bliss J, Burstein H, Cardoso F, Fohler H, Foukakis T, Gelmon KA, Goetz M, Haddad TC, Iwata H, Jassem J, Lee SC, Linderholm B, Los M, Mamounas EP, Miller KD, Morris PG, Munzone E, Gal-Yam EN, Ring A, Shepherd L, Singer C, Thomssen C, Tseng LM, Valagussa P, Winer EP, Wolff AC, Zoppoli G, Machacek-Link J, Schurmans C, Huang X, Gauthier E, Fesl C, Dueck AC, DeMichele A, Gnant M; PALLAS Groups and Investigators. Pfeiler G, et al. Among authors: jassem j. J Clin Oncol. 2023 Nov 20;41(33):5118-5130. doi: 10.1200/JCO.23.00126. Epub 2023 Aug 9. J Clin Oncol. 2023. PMID: 37556775 Clinical Trial.
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
Bearz A, Martini JF, Jassem J, Kim SW, Chang GC, Shaw AT, Shepard DA, Dall'O' E, Polli A, Thurm H, Zalcman G, Garcia Campelo MR, Penkov K, Hayashi H, Solomon BJ. Bearz A, et al. Among authors: jassem j. J Thorac Oncol. 2023 Nov;18(11):1581-1593. doi: 10.1016/j.jtho.2023.07.023. Epub 2023 Aug 3. J Thorac Oncol. 2023. PMID: 37541389 Free article.
470 results